Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study

Table 3 Factors associated with non-sustained virological response to peginterferon-α and ribavirin treatment in chronic hepatitis C patients

		Groups		Univariate analysis		Multivariate analysis
Factors		SVR	Non-SVR	Coefficient	P-value	B	Odds ratio	95 % C.I.
Gender (Male/Female)		4234/3740	2426/3080	106.402	<0.001	−0.302	0.739	0.683–0.800
Age (≥65 years/<65 years)		1865/6093	2079/3414	325.742	<0.001	−0.392	0.676	0.618–0.739
History of IFN treatment (naïve/experienced)		6106/1733	3676/1755	172.508	<0.001	−0.407	0.665	0.610–0.726
Genotype (1/2 + 3)		4386/3439	4577/818	1212.744	<0.001	−1.344	0.261	0.238–0.286
Viral load (high/low)		7204/736	5281/182	178.857	<0.001	−1.213	0.297	0.247–0.359
Pre-AST (U/L)^*		43 [30–69] (n = 7928)	45 [32–68] (n = 5457)		<0.001
Pre-ALT (U/L)^*		54 [31–93] (n = 7931)	48 [31–75] (n = 5459)		<0.001	0.005	1.005	1.004–1.005
Pre-PLT (x10⁴/μL)		17.0 [14.0–21.0] (n = 7855)	15.0 [12.0–19.0] (n = 5374)		<0.001	0.018	1.019	1.009–1.029
FIB-4 index		2.11 [1.36–3.20] (n = 7833)	2.77 [1.86–4.15] (n = 5357)		<0.001	−0.164	0.849	0.821–0.877
Year of starting treatment	– 2008	3062	2327				Reference
	2009	1958	1362	7.949	0.019	−0.085	0.918	0.831–1.015
	2010–	2950	1915	7.949	0.019	−0.095	0.909	0.830–0.997
Region	Hokkaido/Tohoku	941	711			−0.288	0.750	0.653–0.861
	Kanto	547	316			−0.064	0.938	0.786–1.119
	Shin-etsu	361	271			−0.069	0.933	0.765–1.137
	Hokuriku	490	354			−0.032	0.969	0.815–1.152
	Tokai	557	381	21.777	0.005	−0.069	0.934	0.789–1.105
	Kinki	1637	1160			−0.116	0.891	0.790–1.004
	Chugoku	1322	920			−0.044	0.957	0.844–1.085
	Shikoku	314	257			−0.399	0.671	0.546–0.825
	Kyushu	1808	1138				Reference

The values of pre-AST, pre-ALT, pre-PLT, and FIB-4 index are shown as median [interquartile range]
^aSince pre-AST and pre-ALT were closely correlated (r = 0.872; P < 0.001), only pre-ALT was included in multivariate analysis. Significant factors by multivariate analysis are shown in bold. The patients whose treatment outcome could not be determined were excluded from this analysis (n = 576)
ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; C.I., Confidence interval; FIB-4, Fibrosis-4; IFN, Interferon; PLT, Platelets; SVR, Sustained virological response

ISSN: 1471-2458